Want to see UFPT full AI Analyst Report?
Earnings Data
Report Date
Aug 04, 2026TBA (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
2.31Last Year’s EPS
2.5Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call communicated a generally positive operational and strategic trajectory: solid revenue growth (4.1%), strong medical segment performance, margin improvement, meaningful capacity expansions, and successful prior acquisitions. These positives are tempered by short-term headwinds including a 15% decline in nonmedical sales, flat organic growth while new programs ramp, start-up costs dragging near-term EPS, a cyber-related disruption (~$1M of sales shifted and ~$0.5M legal expense), and lingering labor inefficiencies at AJR. Management provided clear mitigation plans (capacity expansion in lower-cost sites, expected ramp in second half, disciplined M&A) and emphasized that many challenges are temporary, supporting an optimistic longer-term outlook.Company Guidance
Top-Line Growth
Revenue increased 4.1% year-over-year (overall sales up ~4%) with medical sales growing 5.9% (reported as 6%), driven by strength in robotic-assisted surgery, patient surfaces & support, and interventional & surgical segments.
Strong Submarket Performance
Notable segment growth: robotic surgery +7%, patient surfaces & support +11%, and interventional & surgical +15%.
Improved Gross Margin
Gross profit margin rose to 28.8% from 28.5% a year ago, despite ongoing labor inefficiencies at AJR.
Solid Adjusted Profitability Metrics
Adjusted operating margin was 16.7% of sales and adjusted diluted EPS was $2.48, up slightly year-over-year.
Operational Wins and Capacity Expansion
Three of four new program launches have already prompted customers to request at least double capacity; company is adding new buildings in Santiago (third building) and La Romana (sixth building) with possession expected in Q2, and planning additional capacity in APAC.
Rapid Growth in Low-Cost Location
Santiago, Dominican Republic revenue increased by more than 200%, enabling better absorption of fixed overhead at that site.
Balance Sheet and Cash Actions
Generated ~$3.2 million in operating cash in Q1, paid down approximately $4 million in debt since March 31, ended the quarter with leverage of ~1.14x and modest capex of $1.7 million.
M&A and Strategic Progress
Prior acquisitions (3 in 2025 and 4 in 2024) are performing well; company remains actively reviewing acquisition opportunities with a disciplined approach to valuation and strategic fit.
Leadership Transition Confidence
Planned CEO transition in June to Mitch Rock is presented as orderly and well-supported; outgoing CEO will remain as Executive Chair to support continuity.
UFPT Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
UFPT Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 04, 2026 | $192.55 | $212.43 | +10.32% |
Feb 24, 2026 | $240.57 | $240.16 | -0.17% |
Nov 03, 2025 | $199.05 | $223.04 | +12.05% |
Aug 04, 2025 | $226.27 | $240.75 | +6.40% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Ufp Technologies (UFPT) report earnings?
Ufp Technologies (UFPT) is schdueled to report earning on Aug 04, 2026, TBA (Confirmed).
What is Ufp Technologies (UFPT) earnings time?
Ufp Technologies (UFPT) earnings time is at Aug 04, 2026, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is UFPT EPS forecast?
UFPT EPS forecast for the fiscal quarter 2026 (Q2) is 2.31.